In an article published on Pharmafile.com, KAUST Professor Lukasz Jaremko delves into the promising realm of targeted cancer drug design. 

Why destroy when we can repair? Professor Jaremko's expert opinion explores the unprecedented potential of structural biology integrating biomolecular dynamics probed by nuclear magnetic resonance (NMR)  to study epigenetic targets, offering a fresh perspective on cancer treatment for the pharmaceutical industry.

Read the article here